Scientific Publications
2026
1.
Colombo C, Medino P, Cipolli M, Lucca F, Cucchetto G, et al.
COVID-19 in people with Cystic Fibrosis beyond the pre-omicron era: a prospective study with a specific focus on long COVID.
J Cyst Fibros. 2026 Jan;25(1):172-178. doi: 10.1016/j.jcf.2025.08.015.
2025
1.
Alameeri A, Yavuz BC, Lucca F, Bambir I, Famulska P, W F Cohen R.
Cystic fibrosis year in review 2024.
J Cyst Fibros. 2025 Mar;24(2):218-223. doi: 10.1016/j.jcf.2025.02.012. Epub 2025 Feb 18.PMID: 39971692
2.
Bezzerri V, Cipolli M.
Beyond the bench: Revitalizing ataluren development for rare genetic disorders.
Mol Ther. 2025 Jun 21:S1525-0016(25)00453-8. doi: 10.1016/j.ymthe.2025.06.002. Online ahead of print.PMID: 40544842
3.
Bezzerri V, Pegoraro A, Hristodor AM, Crane GM, Meneghelli I, Brignole C, Boni C, Baldisseri E, Vella A, Menichetti G, Valli R, Porta G, D’Amico G, Tecchio C, Parisi A, Lippi G, Mercuri A, Cesaro S, Corey S, Cipolli M.
Ataluren improves hematopoietic and pancreatic disorders in Shwachman-Diamond syndrome patients: a compassionate program case-series.
Nat Commun 16, 8189 (2025). doi: 10.1038/s41467-025-63137-3
Download (PDF)
4.
Bezzerri V, Putignani L, Mantuano E, Polini A, Navarini L, Vomero M, Corberi E, Miacci V, Papuc PE, Schiavone V, Costa G.
A Focus on Inflammatory and Bacterial Biomarkers in Secondary Peritonitis.
Cells, 2025 Oct 22;14(21):1653. doi: 10.3390/cells14211653.
5.
Buniotto F, Tridello G, De Scolari A, Meneghelli I, Pintani E, Perobelli S, Cipolli M.
Improved quality of life in cystic fibrosis patients observed up to 36 months after starting Elexacaftor/Tezacaftor/Ivacaftor treatment.
J Patient Rep Outcomes. 2025 May 6;9(1):48. doi: 10.1186/s41687-025-00879-0.
6.
Carta F, Malvezzi A, Innocenti D, d’Ippolito M, Piermarini I, Retucci M, Colombo C and Gambazza S; the CrISP Study Group.
Association of age, hospitalizations, and physical activity with urinary incontinence in cystic fibrosis: a multicenter cross-sectional study.
Ther Adv Respir Dis. 2025 Vol. 19: 1–14. doi: 10.1177/175346662513974.
7.
Cipolli M, Thorat T, Pafundi PC, Roggeri A, Roggeri DP, Rossi C, Pintani E, Meneghelli I, Lucca F, Fratoni A, Vega‑Hernandez G.
Real‑World Impact of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Italy: A Retrospective Study from a Cystic Fibrosis Center.
Pulm Ther. 2025 Dec 4. doi: 10.1007/s41030-025-00334-x.
8.
Conti J, Angyal D, Kleinfelder K, Latorre RV, Calicchia M, Farinazzo A, Rodella L, Tomba F, Massella A, Frulloni L, Taccetti G, Terlizzi V, Leung A, Groeneweg TA, Bijvelds MJC, Melotti P, Sorio C.
Evaluation of the response to elexacaftor-tezacaftor-ivacaftor of the rare CFTR variants L383S, I507del, L1065P and R1066H in intestinal organoid-derived epithelial monolayers.
J Cyst Fibros. 2025 May;24(3):552-561. doi: 10.1016/j.jcf.2025.02.008. Epub 2025 Feb 19.
9.
Dobi D, Rimessi A, Loberto N, Mauri L, Bassi R, Chiricozzi E, Olioso D, Pellielo G, Pinton P, Bezzerri V, Cabrini G, Lippi G, Tamanini A, Lunghi G, Aureli M.
Effects of GM1 ganglio-side and its derivatives on ETI-rescued F508del-CFTR maturation and host-pathogen interactions in cystic fibrosis bronchial cells.
Glycoconj J. 2025 Aug;42(3-4):173-186. doi: 10.1007/s10719-025-10191-0. Epub 2025 Jul 15.
10.
Gramegna A, Cimino G, Cipolli M, Gandini G, Calderazzo MA, Profiti A, Piedepalumbo F, Blasi F.
Impact of elexacaftor/tezacaftor/ivacaftor (ETI) on the prescription refill rate (PRR) for inhaled medications in people with CF: an Italian multicenter analysis.
Respir Res. 2025 Jan 18;26(1):19. doi: 10.1186/s12931-024-03089-2.PMID: 39827103
11.
Hristodor AM, Cappelli E, Baldisseri E, Valli R, Montalbano G, Micheloni G, Porta G, Frattini A, Ravera S, Fioredda F, Lippi G, Dufour C, Cipolli M, Bezzerri V.
Development of translational read-through-inducing drugs as novel therapeutic options for patients with Fanconi anemia.
Cell Death Discov. 2025 Jun 21;11(1):286. doi: 10.1038/s41420-025-02571-0.PMID: 40544182
12.
Lopetuso LR, Murgiano M, Mantuano E, Schiavone V, Costa A, Mascianà G, Bezzerri V, Costa G.
The Molecular Landscape of In-flammation in Inflammatory Bowel Disease (IBD): Targets for Precision Medicine.
Bio-medicines. 2025 Nov 9;13(11):2738. doi: 10.3390/biomedicines13112738.
13.
Lucca F, Meneghelli I, Tridello G, Buniotto F, Cucchetto G, Volpi S, Pintani E, Bezzerri V and Cipolli M.
Reported Adverse Events in Patients with CF Receiving Treatment with Elexacaftor/Tezacaftor/Ivacaftor: 5 Years Observational Study.
J Clin Med 2025, 14, 4335. doi: 10.3390/jcm14124335
14.
Lucca F, Volpi S, Ros M, Fabrizzi B, Meneghelli I, Bordicchia M, Buniotto F, Lancini A, Brignole C, Pauro F, Bezzerri V and Cipolli M.
Elexacaftor/Tezacaftor/Ivacaftor Efficacy in a Cohort of Italian Patients with CFTR Rare Mutations.
Int J Transl Med 2025, 5(1), 11. doi: 10.3390/ijtm5010011
15.
Minelli A, Pintani E, Valli R, Tridello G, Porta G, Fioredda F, Cipolli M, Danesino C.
Shwachman-Diamond Syndrome and Diabetes: An Update from the Italian Registry and Review of the Literature.
Exp Clin Endocrinol Diabetes. 2025 Feb;133(2):78-82. doi: 10.1055/a-2460-6977. Epub 2025 Jan 15.PMID: 39814041
16.
Nicosia L, Pranke I, Latorre RV, Murray JB, Lonetti L, Cavusoglu-Doran K, Dreano E, Costello JP, Carroll M, Melotti P, Sorio C, Sermet-Gaudelus I, Scallan MF, Harrison PT.
Adenine base editing with engineered virus-like particles rescues the CFTR mutation G542X in patient-derived intestinal organoids.
iScience. 2025 Feb 21;28(3):111979. doi: 10.1016/j.isci.2025.111979. eCollection 2025 Mar 21.PMID: 40144632
17.
Oyarbide U, Bezzerri V, Staton M, Boni C, Shah A, Cipolli M, Calo E, Corey SJ.
Reduced EIF6 dosage attenuates TP53 activation in models of Shwachman-Diamond syndrome.
J Clin Invest. 2025 Feb 18;135(8):e187778. doi: 10.1172/JCI187778. eCollection 2025 Apr 15.PMID: 39964763
18.
Piona C, Mozzillo E, Tosco A, Zusi C, Emiliani F, Volpi S, Di Candia F, Raia V, Boselli ML, Trombetta M, Cipolli M, Bonadonna RC, Maffeis C.
A Longitudinal Study of Glucose Tolerance in Cystic Fibrosis: The Central Role of Beta Cell Functional Mass.
J Clin Endocrinol Metab. 2025 Apr 22;110(5):e1670-e1677. doi: 10.1210/clinem/dgae474.PMID: 38994570
19.
Ricupito R, Bravi M, Santacaterina F, Campardo G, Guarise R, Castellucci R, Alaoui I. B. Forelli F. Biomechanical Alterations in the Unweight Phase of the Single-Leg Countermovement Jump After ACL Reconstruction.
J Funct Morphol Kinesiol. 2025, 10, 296. doi: 10.3390/jfmk10030296
20.
Sabbioni G, D’Aversa E, Breveglieri G, Altieri MT, Boni C, Pegoraro A, Finotti A, Gambari R, D’Amico G, Vella A, Lippi G, Cipolli M, Bezzerri V, Borgatti M.
Constitutive systemic inflammation in Shwachman-Diamond Syndrome.
Mol Med. 2025 Feb 28;31(1):81. doi: 10.1186/s10020-025-01133-5.PMID: 40021961
21.
Saitta GM, Veschetti L, Feletti R, Sandri A, Boaretti M, Melotti P, Carelli M, Lleò MM, Malerba G, Signoretto C.
Development of a Simple and Accurate Molecular Protocol Using 16SrRNA for Species-Specific Identification of Achromobacter spp.
Pathogens. 2025 Mar 12;14(3):271. doi: 10.3390/pathogens14030271.
22.
Terlizzi V, Fevola C, Presti S, Claut L, Ambroni M, Calderazzo MA, Esposito I, Fabrizzi B, Leonetti G, Lombardo M, Maschio M, Palladino N, Pauro F, Pisi G, Ripani P, Ros M, Rotolo N, Salvatore D, Sepe A, Termini L, Timpano S, Troiani P, Vitullo P, Zanda M, Blasi F, Castellani C.
Critical Issues in the Management of CRMS/CFSPID Children: A National Real-World Survey.
Pediatr Pulmonol. 2025 Jan;60(1):e27483. doi: 10.1002/ppul.27483.PMID: 39812351
23.
Venditto L, Dolce D, Campana S, Vitullo P, Di Maurizio M, Fevola C, Lucca F, Taccetti G, Terlizzi V.
Nocardia Isolation in People with Cystic Fibrosis and Non-CF Bronchiectasis: A Multicenter Italian Study.
Antibiotics (Basel). 2025 Mar 18;14(3):317. doi: 10.3390/antibiotics14030317. PMID: 40149127